BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

Who Took Part

According to the abstract, 885 patients were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Patients were treated for a single migraine attack.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with CGRP (Calcitonin Gene-Related Peptide) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Acute Disease, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders, Piperidines, Pyridines and Serotonin 5-HT1 Receptor Agonists.

The authors tagged it with the keywords BMS-927711 and double-blind.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in 885 patients in people with migraine.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Cephalalgia : an international journal of headache), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.